Form 8-K · Current report
Stryker Corporation 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0000310764
- Accession no.
- 0000310764-26-000048
Summary
Stryker reported second-quarter 2026 net sales of $6.6 billion, up 9.4% year over year with 9.0% organic growth, reported diluted EPS of $3.30 (up 44.1%) and adjusted EPS of $3.69 (up 17.9%). The company narrowed its full-year 2026 guidance to organic net sales growth of 8.3%–9.3% and adjusted EPS of $14.95–$15.10, and Chair and CEO Kevin A. Lobo said Stryker made significant progress recovering from the cyber incident first reported on March 11, 2026.
Key points
- Reported net earnings rose 44.3% to $1.3 billion, and adjusted operating income margin rose 170 basis points to 27.4%.
- MedSurg and Neurotechnology net sales rose 9.7% to $3.6 billion; Orthopaedics net sales rose 9.1% to $3.0 billion.
- Organic sales growth came from increased unit volume, with a modestly positive pricing impact included in the full-year sales guidance.
- Stryker said foreign exchange is expected to have a slightly favorable impact on both sales and adjusted EPS if rates hold near current levels.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION Stryker Corporation issued a press release on July 30, 2026 announcing its second quarter 2026 operating results. A copy of this press release is attached hereto as Exhibit 99.1. The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.